IMNN announces 2026 R&D Day highlighting Phase 3 OVATION 3
IMUNON says it will host a 2026 R&D Day featuring Phase 3 OVATION 3 and the clinical potential of IMNN-001.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.